(Q45713744)

15 December 2017

title

A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis (English)

1 reference

15 December 2017

1 reference

Mansfield JC

1

1 reference

15 December 2017

Giaffer MH

2

1 reference

15 December 2017

Cann PA

3

1 reference

15 December 2017

McKenna D

4

1 reference

15 December 2017

Thornton PC

5

1 reference

15 December 2017

Holdsworth CD

6

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

Alimentary Pharmacology & Therapeutics

15 December 2017

published in

1 reference

15 December 2017

volume

16

1 reference

15 December 2017

issue

1

1 reference

15 December 2017

page(s)

69-77

1 reference

An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis

15 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01151.X

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01151.X

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01151.X

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01151.X

Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01151.X

Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01151.X

Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01151.X

Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01151.X

Transdermal nicotine for active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01151.X

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01151.X

10.1046/J.1365-2036.2002.01151.X

21 January 2018

Identifiers

DOI

1 reference

15 December 2017

1 reference